Cleared Traditional

K251217 - SmartGuard technology (FDA 510(k) Clearance)

Also includes:
Predictive Low Glucose technology
Aug 2025
Decision
130d
Days
Class 2
Risk

K251217 is an FDA 510(k) clearance for the SmartGuard technology. This device is classified as a Interoperable Automated Glycemic Controller (Class II - Special Controls, product code QJI).

Submitted by Medtronic Minimed, Inc. (Northridge, US). The FDA issued a Cleared decision on August 29, 2025, 130 days after receiving the submission on April 21, 2025.

This device falls under the Chemistry FDA review panel. Regulated under 21 CFR 862.1356. An Interoperable Automated Glycemic Controller Is A Device Intended To Automatically Calculate Drug Doses Based On Inputs Such As Glucose And Other Relevant Physiological Parameters, And To Command The Delivery Of Such Drug Doses From A Connected Infusion Pump. Interoperable Automated Glycemic Controllers Are Designed To Reliably And Securely Communicate With Digitally Connected Devices To Allow Drug Delivery Commands To Be Sent, Received, Executed, And Confirmed. Interoperable Automated Glycemic Controllers Are Intended To Be Used In Conjunction With Digitally Connected Devices For The Purpose Of Maintaining Glycemic Control..

Submission Details

510(k) Number K251217 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received April 21, 2025
Decision Date August 29, 2025
Days to Decision 130 days
Submission Type Traditional
Review Panel Chemistry (CH)
Summary Summary PDF

Device Classification

Product Code QJI — Interoperable Automated Glycemic Controller
Device Class Class II - Special Controls
CFR Regulation 21 CFR 862.1356
Definition An Interoperable Automated Glycemic Controller Is A Device Intended To Automatically Calculate Drug Doses Based On Inputs Such As Glucose And Other Relevant Physiological Parameters, And To Command The Delivery Of Such Drug Doses From A Connected Infusion Pump. Interoperable Automated Glycemic Controllers Are Designed To Reliably And Securely Communicate With Digitally Connected Devices To Allow Drug Delivery Commands To Be Sent, Received, Executed, And Confirmed. Interoperable Automated Glycemic Controllers Are Intended To Be Used In Conjunction With Digitally Connected Devices For The Purpose Of Maintaining Glycemic Control.